Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib plus pemetrexed/cisplatin for first-line nonsquamous non-small cell lung cancer
NL-OMON41950Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ruxolitinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Incyte. Primary endpoints: Safe and tolerable ruxolitinib dose in combination with pemetrexed/cisplatin and Overall survival. Started Dec 2015; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON41950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41950.